Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. [electronic resource]
Producer: 20090217Description: 519-33 p. digitalISSN:- 1525-2191
- Adipocytes -- cytology
- Animals
- Antibiotics, Antineoplastic -- toxicity
- Bleomycin -- toxicity
- Cell Differentiation -- drug effects
- Cell Movement -- drug effects
- Collagen -- drug effects
- Female
- Fibrosis -- chemically induced
- Flow Cytometry
- Fluorescent Antibody Technique
- Gene Expression -- drug effects
- Hypoglycemic Agents -- pharmacology
- Immunohistochemistry
- Inflammation -- chemically induced
- Mice
- Mice, Inbred BALB C
- PPAR gamma -- drug effects
- Reverse Transcriptase Polymerase Chain Reaction
- Rosiglitazone
- Scleroderma, Systemic -- chemically induced
- Stem Cells -- cytology
- Thiazolidinediones -- pharmacology
- Transforming Growth Factor beta1 -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.